Quest Diagnostics (DGX) Tops Q3 EPS by 19c; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Quest Diagnostics Reports Third Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
October 20, 2022 6:45 AM EDTThird quarter revenues of $2.49 billion, down 10.4% from 2021Third quarter reported diluted earnings per share ("EPS") of $2.17, down 46.0% from 2021; and adjusted diluted EPS of $2.36, down 40.4% from 2021Third quarter base business revenues of $2.17 billion, up 5.1% from 2021Full year 2022 reported diluted EPS now expected to be between $8.52 and $8.72; and adjusted diluted EPS expected to be between $9.75 and $9.95
SECAUCUS, N.J., Oct. 20, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2022.
... More